Skip to main content

Certain Prostate Meds Might Help Prevent Dementia

Medically reviewed by Carmen Pope, BPharm. Last updated on June 20, 2024.

By Dennis Thompson HealthDay Reporter

WEDNESDAY, June 20, 2024 -- Prostate medications might help reduce the risk of a specific type of dementia, a new study suggests.

People were less likely to develop Lewy body dementia when taking drugs designed to treat urinary symptoms caused by an enlarged prostate, researchers reported June 19 in the journal Neurology.

“These results are exciting, because right now there are no drugs to prevent or treat dementia with Lewy bodies, which is the second most common neurodegenerative type of dementia after Alzheimer’s disease,” said researcher Jacob Simmering, an assistant professor of internal medicine with the University of Iowa.

“If we can determine that an existing drug can offer protection against this debilitating disease, that has the potential to greatly reduce its effects,” Simmering added in a journal news release.

Lewy body dementia affects more than 1 million people in the United States, according to the National Institute on Aging (NIA). It’s caused by the protein alpha-synuclein, which forms abnormal deposits called Lewy bodies that affect chemicals in the brain.

This form of dementia can cause thinking and memory issues, movement problems and even visual hallucinations, the NIA says. More than 80% of people with Lewy body dementia see things that aren’t really there.

For this study, researchers focused on the drugs terazosin, doxazosin and alfuzosin, which help men urinate more easily despite an enlarged prostate. These meds help relax muscles in the prostate and bladder.

However, the three drugs also activate an enzyme important for energy production in brain cells, and previous studies have shown a link between these drugs and Parkinson’s disease, researchers said.

Lewy body dementia is similar to Parkinson’s, so researchers decided to see if the drugs might help these patients as well.

Researchers analyzed data on more than 126,000 men taking one of the three drugs, and compared them against more than 517,000 men taking two other types of prostate medication that don’t activate that enzyme.

Results show that men taking one of the three drugs were around 40% less likely to develop Lewy body dementia than those taking the two other meds.

“More research is needed to follow people over time and determine whether there is a cause-and-effect relationship here, but it is promising to think that these drugs could have a protective effect on this disease that will likely affect a larger number of people as the population ages,” Simmering said.

Researchers warned that since only men were included in the study, the results might not apply to women. Lewy body dementia appears to affect slightly more men than women, the NIA notes.

In addition, Lewy body dementia can be tough to diagnose, so it’s possible the researchers didn’t catch everyone who’d developed the brain disease.

Sources

  • American Academy of Neurology, news release, June 19, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted June 2024

Read this next

Couch Potatoes Have Greater Risk Of Brain Decline, Even If They Exercise

MONDAY, May 19, 2025 — Couch potatoes are more likely to develop Alzheimer’s disease, even if they set aside time to work out each day, a new study says. People who...

FDA Gives Marketing Nod to Blood Test for Diagnosing Alzheimer Disease

FRIDAY, May 16, 2025 -- The first in vitro diagnostic device that uses blood samples to detect Alzheimer disease has been granted marketing clearance by the U.S. Food and Drug...

Alzheimer’s Drug Leqembi Can Be Safely Administered In Memory Clinics, Study Says

THURSDAY, May 15, 2025 — The 2023 approval of the first drug shown to slow the progression of Alzheimer’s disease came with no small amount of concern from...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.